Related Experiment Video
Updated: Jun 10, 2026

Laparoscopic Radical Gastrectomy for Remnant Gastric Cancer
Published on: October 31, 2025
Don't Cancer Doctors Offer Good-Quality Care?
Douglas W Blayney1, Micheal N Neuss2
1Stanford Medicine, Stanford University School of Medicine, Stanford, CA.
None:
We offer the perspectives of two veterans on the last quarter century of quality improvement efforts in oncology care. We believe that our colleagues deliver high quality care, but challenges remain in demonstrating this assertion to patients, payers, policy makers and to our colleagues. The journey began with the American College of Surgeons (ACOS) establishing minimum standards for cancer surgery in 1919 and evolved through state cancer registries, culminating in the Surveillance, Epidemiology, and End Results (SEER) program. Donabedian's structure-process-outcome framework and Porter's value equation provided conceptual frameworks for action. ASCO developed the Quality Oncology Practice Initiative (QOPI) in 2002. Physician-led self-assessment and chart abstraction could drive improvement. QOPI expanded to include certification programs and safety standards. Integrating quality measurement and improvement with payment incentives has proven challenging. Medicare's successive payment reform attempts-from Resource-Based Relative Value (RBRVS) through the Oncology Care Model (OCM) to the Enhancing Oncology Model-have shown mixed results, with minimal to no improvements in quality measures and limited cost-savings. Private payer initiatives based on clinical pathways largely failed to reduce costs and have been scaled back. Contemporary challenges include vertical integration of health care systems without clear quality benefits, rising drug costs, physician burnout, and erosion of public trust. New tools and iterations offer hope: artificial intelligence (AI)-powered clinical documentation and analysis could dramatically reduce administrative burdens, cross-platform electronic record sharing should enable longitudinal quality analysis, and restoration of patient agency through market forces and social media may better align quality incentives. We posit that better future results require returning to bottom-up, physician-led quality improvement while leveraging AI and data-sharing technologies to make quality measurement a natural component of cancer care rather than an externally imposed burden.
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
Cancer
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Prevention
Some...